Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Supplementary Information
Detailed Submission Data
Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/ home recorded data.
Overview of Innovation:
MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.
MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g. HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.

THE PRODUCT:
MDMW is a portal/ app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clinician guidance driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content3
Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes  to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/  home recorded data.
Overview of Innovation:

MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland ,and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.
MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g.HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.
 
THE PRODUCT:
MDMW is a portal/ app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clincian guidelien driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737  
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
MyDiabetesMyWay is a novel patient facing intervention which can directly impact on clinical outcomes, quality of life, and improve efficiencies in service delivery. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population. Good patient self-management driven by education, empowerment and motivation is key to good outcomes. Diabetes spending may rise over 10 years to c. 17% of the NHS budget. 

People with diabetes only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; i.e. - blood glucose monitoring, medication adjustment, appropriate daily foot care, weight management and dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications. 
 
MyDiabetesMyWay delivers cost savings and better outcomes for patients (ref: published evidence), it also improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs.
 
Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget.  Long-term conditions management needs to evolve to reap the potential benefits of data driven approaches. There is massive potential for wider lifestyle/home monitoring/institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.

MDMW can contribute to the local implementation of the NHS Long Term Plan. EG:

3.81 supporting delivery across primary care to enable more to acheive treatment targets
5.9 & 5.13 People seamlessly empowered by digital tools information and services/digital structured education.

Demonstrable through Tests 2/3/4 (£ releasing/reduce demand for care/reduce of unwarrant
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
MyDiabetesMyWay can directly impact clinical outcomes such as HbA1C, quality of life, motivation and knowledge, and improve efficiencies in service delivery (ROI at least 4:1)- see published evidence. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population over the age of 16. Good patient self-management driven by flexible access to good quaity information (available in a range of languages), structured education courses, empowerment and motivation is key to good outcomes. MDMW supports acheivement of local 3 treatment (BP, cholesterol and HbA1C) and structured education targets.
People with diabetes (PWD) only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; includes blood glucose (sugar) monitoring, medication adjustment, appropriate daily foot care, weight management and correct dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications. 
 
MyDiabetesMyWay delivers cost savings and  better outcomes for patients and  improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. This combination of empowered PWD and practitioners with a more complete picture can lead to more frequent co-production of health with the patient at the heart of decision making.

Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs. 
 
Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget.  Long-term conditions management needs to evolve to reap the benefits of data-driven approaches. There is massive potential for wider lifestyle/ home monitoring/ institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.
Current and planned activity: 
MDMW is currently deployed throughout NHS Scotland. MyWay Digital Health are now implemented/ing MDMW in sites in NHS England, including Somerset, NW London and Greater Manchester. We were selected as one of 11 NHS innovation accelerator programme fellows (2018 cohort) and the Digital Health London accelerator, both of which are supporting adoption.

We continue to develop the product including Artifical intelligence/machine learning, decision support and a corresponding clinician platform through Innovation funding.

This will further enable delivery of the long Term Plan and section 5.29:

"Decision support and AI ... technologies need to be embraced by the NHS, but also subjected to the same scrutiny that we would apply to any other medical technology. In the coming years AI will make it possible for many tasks to be automated, quality to increase and staff to focus on the complexity of human interactions that technology will never master.
See files for company skill profile.
What is the intellectual property status of your innovation?:
Intellectual Poperty for MDMW is fully assigned to the company from the University of Dundee for exploitation
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Co-Authors:
Regulatory Approvals:

IGToolkit was secured in late January 2018. We’ve adopted ISO 27001 policies and procedures (inc. provision for GDPR) and completed the Stage 1 assessment in early Feb 2018; the date for Stage 2 is May 2018 . The first big implementation of our system outside NHS Scotland is in Somerset, the Caldicott Guardian for Somerset CCG recently signed-off on our system, and it was endorsed by the Local Medical Committee as well as senior clinicians across the county. We aim to begin securing ISO 13485 as well as CE Device Marking later in 2018. We recently underwent a thorough successful regulatory review as part of the ITP assessment process (through ourmobilehealth)- report can be sent on for review.
Commercial information:
We already have a market ready My Diabetes My Way patient portal (operating at scale) although new features continue to be developed including remote monitoring and communication tools (July 2018) and a dedicated smartphone app (May 2018). We are also developing 2 new products MyDiabetes*Clinical (clinician diabetes EHR and quality improvement/ dashboard tools), and MyDiabetes*IQ (machine learning platform to support model building and decision support algorithms leading to alerting and notifications for patients and clinicians). 
for more information see; http://www.mywaydigitalhealth.co.uk/products/
Regional Scalability:
Implemented at scale across NHS Scotland since 2008 (currently> 35,000 registrants), Implementing in Somerset CCG and across NW London STP. Working on applications in Greater Manchester and other areas
Measures:
Previous Assesment in NHS Scotland:

MDMW clinical impact has been assessed (April 2017) using time-series analysis comparing HbA1c of active users with those in the inactive background patient population (control cohort) matched by age, duration of diabetes, socioeconomic status and gender (7147 interventions (registrants and active users) vs 36020 matched subjects). My Diabetes My Way (MDMW) users demonstrated a sustained 4 mmol/mol HbA1C reduction. Further health economic analysis based on UKPDS complications models and £1 per diabetes population annual charge/ 5-10% registration, suggests a return on investment of around 6:1. User surveys; 90% feel MDMW supports diabetes knowledge, self-management and motivation.

Ongoing Assessment:

- Identifying strategies/ barriers for successful implementation and uptake.
- Gather feedback on new product feature to assist in ongoing product development
- Assess changes in health outcomes, complications prevention and health economic benefits 
- Assess changes in working practices/ care delivery efficiencies e.g. impact on consultation numbers, face to face education, unnecessary screening tests


*Outcomes will be added to the health economic model
 

 
Adoption target:
We would aim to offer to everyone in the region with diabetes and rapidly onboard 5-10% of the entire diabetes population in your area in the first 12 months. Our intervention USP is low cost and scalability (at no additional per person cost).
Investment sought:
No investment sought currently
Read more
Hide details
Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/ home recorded data.
Overview of Innovation:
MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland ,and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.

MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g.HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.

THE PRODUCT:
MDMW is a portal/app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clincian guidance driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
MyDiabetesMyWay is a novel patient facing intervention which can directly impact on clinical outcomes, quality of life, and improve efficiencies in service delivery. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population. Good patient self-management driven by education, empowerment and motivation is key to good outcomes. Diabetes spending may rise over 10 years to c. 17% of the NHS budget.

People with diabetes only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; i.e. - blood glucose monitoring, medication adjustment, appropriate daily foot care, weight management and dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MyDiabetesMyWay delivers cost savings and better outcomes for patients (ref: published evidence), it also improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs.

Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget. Long-term conditions management needs to evolve to reap the potential benefits of data driven approaches. There is massive potential for wider lifestyle/home monitoring/institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.

MDMW can contribute to the local implementation of the NHS Long Term Plan. EG:

3.81 supporting delivery across primary care to enable more to achieve treatment targets
5.9 & 5.13 People seamlessly empowered by digital tools information and services/digital structured education.

Demonstrable through Tests 2/3/4 (£ releasing/reduce demand for care/reduce of unwarrant)

 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population over the age of 16. Good patient self-management driven by flexible access to good quality information (available in a range of languages), structured education courses, empowerment and motivation is key to good outcomes. MDMW supports achievement of local 3 treatment (BP, cholesterol and HbA1C) and structured education targets.

People with diabetes (PWD) only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; includes blood glucose (sugar) monitoring, medication adjustment, appropriate daily foot care, weight management and correct dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MDMW delivers cost savings and better outcomes for patients and improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. This combination of empowered PWD and practitioners with a more complete picture can lead to more frequent co-production of health with the patient at the heart of decision making.

Digital Health Innovations - MDMW can deliver in the following categories: 
  • Health Maintenance – MDMW is a patient support platform for those with diabetes and the combination of data linkage/their own data and information/structured education enhances motivation to self-manage.
  • Access – by accessing their records and data remotely patients can choose to access health care, we have a clinical system just starting to deploy which can further enhance this.
  • Pathways – as we build (in collaboration with the local diabetes services) a website containing all local services and which acts as the access point to all the assets in MDMW we act as a signpost to patients (we do not provide real time capacity information at this point).
  • Integration/data visualisation - this is a strength of My Way Digital Health – we specialise in data integration and provide this to patients and health care professionals in different ways. The patient visualisations are particularly powerful and helpful. E.g. 90% of patients report an improvement in the quality of their consultations as a result of using MDMW.
Current and planned activity: 
MDMW is currently deployed throughout NHS Scotland. MyWay Digital Health are now implemented/ing MDMW in sites in NHS England, including Somerset, NW London and Greater Manchester. We were selected as one of 11 NHS innovation accelerator programme fellows (2018 cohort) and the Digital Health London accelerator, both of which are supporting adoption.

We continue to develop the product including Artificial intelligence/machine learning, decision support and a corresponding clinician platform through Innovation funding.

This will further enable delivery of the long Term Plan and section 5.29:

"Decision support and AI ... technologies need to be embraced by the NHS, but also subjected to the same scrutiny that we would apply to any other medical technology. In the coming years AI will make it possible for many tasks to be automated, quality to increase and staff to focus on the complexity of human interactions that technology will never master.
See files for company skill profile.
What is the intellectual property status of your innovation?:
Intellectual Property for MDMW is fully assigned to the company from the University of Dundee for exploitation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
Implemented at scale across NHS Scotland since 2008 (currently> 35,000 registrants), Implementing in Somerset CCG and across NW London STP. Working on applications in Greater Manchester and other areas.
Measures:
Previous Assessment in NHS Scotland:

MDMW clinical impact has been assessed (April 2017) using time-series analysis comparing HbA1c of active users with those in the inactive background patient population (control cohort) matched by age, duration of diabetes, socioeconomic status and gender (7147 interventions (registrants and active users) vs 36020 matched subjects). My Diabetes My Way (MDMW) users demonstrated a sustained 4 mmol/mol HbA1C reduction. Further health economic analysis based on UKPDS complications models and £1 per diabetes population annual charge/ 5-10% registration, suggests a return on investment of around 6:1. User surveys; 90% feel MDMW supports diabetes knowledge, self-management and motivation.

Ongoing Assessment:

- Identifying strategies/ barriers for successful implementation and uptake.
- Gather feedback on new product feature to assist in ongoing product development
- Assess changes in health outcomes, complications prevention and health economic benefits 
- Assess changes in working practices/ care delivery efficiencies e.g. impact on consultation numbers, face to face education, unnecessary screening tests

*Outcomes will be added to the health economic model
Adoption target:
We would aim to offer to everyone in the region with diabetes and rapidly onboard 5-10% of the entire diabetes population in your area in the first 12 months. Our intervention USP is low cost and scalability (at no additional per person cost).
Read more
Hide details
Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/ home recorded data.
Overview of Innovation:
MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.

MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g. HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.

THE PRODUCT:
MDMW is a portal/ app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clinician guidance driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health
Benefit to NHS:
MyDiabetesMyWay is a novel patient facing intervention which can directly impact on clinical outcomes, quality of life, and improve efficiencies in service delivery. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population. Good patient self-management driven by education, empowerment and motivation is key to good outcomes. Diabetes spending may rise over 10 years to c. 17% of the NHS budget.

People with diabetes only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; i.e. - blood glucose monitoring, medication adjustment, appropriate daily foot care, weight management and dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MyDiabetesMyWay delivers cost savings and better outcomes for patients (ref: published evidence), it also improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs.

Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget. Long-term conditions management needs to evolve to reap the potential benefits of data driven approaches. There is massive potential for wider lifestyle/home monitoring/institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.

MDMW can contribute to the local implementation of the NHS Long Term Plan. EG:

3.81 supporting delivery across primary care to enable more to acheive treatment targets
5.9 & 5.13 People seamlessly empowered by digital tools information and services/digital structured education.

Demonstrable through Tests 2/3/4 (£ releasing/reduce demand for care/reduce of unwarrant).
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population over the age of 16. Good patient self-management driven by flexible access to good quaity information (available in a range of languages), structured education courses, empowerment and motivation is key to good outcomes. MDMW supports acheivement of local 3 treatment (BP, cholesterol and HbA1C) and structured education targets.

People with diabetes (PWD) only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; includes blood glucose (sugar) monitoring, medication adjustment, appropriate daily foot care, weight management and correct dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MDMW delivers cost savings and better outcomes for patients and improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. This combination of empowered PWD and practitioners with a more complete picture can lead to more frequent co-production of health with the patient at the heart of decision making.
               
Identification, prevention and management of diabetes
 
We fit firmly in the management of diabetes section, but as we are continually developing our resources – we have a prevention structured education course in development.
Current and planned activity: 
MDMW is currently deployed throughout NHS Scotland. MyWay Digital Health are now implemented/ing MDMW in sites in NHS England, including Somerset, NW London and Greater Manchester. We were selected as one of 11 NHS innovation accelerator programme fellows (2018 cohort) and the Digital Health London accelerator, both of which are supporting adoption.

We continue to develop the product including Artifical intelligence/machine learning, decision support and a corresponding clinician platform through Innovation funding.

This will further enable delivery of the long Term Plan and section 5.29:

"Decision support and AI ... technologies need to be embraced by the NHS, but also subjected to the same scrutiny that we would apply to any other medical technology. In the coming years AI will make it possible for many tasks to be automated, quality to increase and staff to focus on the complexity of human interactions that technology will never master.
See files for company skill profile.
What is the intellectual property status of your innovation?:
Intellectual Property for MDMW is fully assigned to the company from the University of Dundee for exploitation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
Implemented at scale across NHS Scotland since 2008 (currently> 35,000 registrants), Implementing in Somerset CCG and across NW London STP. Working on applications in Greater Manchester and other areas.
Measures:
Previous Assessment in NHS Scotland:

MDMW clinical impact has been assessed (April 2017) using time-series analysis comparing HbA1c of active users with those in the inactive background patient population (control cohort) matched by age, duration of diabetes, socioeconomic status and gender (7147 interventions (registrants and active users) vs 36020 matched subjects). My Diabetes My Way (MDMW) users demonstrated a sustained 4 mmol/mol HbA1C reduction. Further health economic analysis based on UKPDS complications models and £1 per diabetes population annual charge/ 5-10% registration, suggests a return on investment of around 6:1. User surveys; 90% feel MDMW supports diabetes knowledge, self-management and motivation.

Ongoing Assessment:

- Identifying strategies/ barriers for successful implementation and uptake.
- Gather feedback on new product feature to assist in ongoing product development
- Assess changes in health outcomes, complications prevention and health economic benefits 
- Assess changes in working practices/ care delivery efficiencies e.g. impact on consultation numbers, face to face education, unnecessary screening tests

*Outcomes will be added to the health economic model
Adoption target:
We would aim to offer to everyone in the region with diabetes and rapidly onboard 5-10% of the entire diabetes population in your area in the first 12 months. Our intervention USP is low cost and scalability (at no additional per person cost).
Read more
Hide details
0
0
Votes
-99999

Created by

Share and Follow